Effects of a Double-Blind, Single Dose of PER977 Administered Alone, and Following a Single Dose of Edoxaban

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

83 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-07-31

Study Completion Date

2013-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

PER977 monotherapy and co-administration following 60 mg edoxaban will have an acceptable safety and tolerability profile with no impact on pro-coagulant biomarkers. A dose of PER977 that reverses the effects of edoxaban on the pharmacodynamic (PD) biomarkers (point of care prothrombin time \[PoC-PT\]), and/or secondary biomarkers (thromboelastography reaction time \[TEG-R\]) will be identified.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of PER977 Administered to Subjects With Steady State Edoxaban Dosing and Re-anticoagulation With Edoxaban

NCT02207257

Anticoagulation Reversal

COMPLETED PHASE2

Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of PER977 Following Heparin

NCT02206087

Healthy

COMPLETED PHASE1/PHASE2

PK and PD of Single, Escalating Doses of PER977 Following Enoxaparin

NCT02206100

Healthy

COMPLETED PHASE1/PHASE2

A Two-part Study in Edoxaban-treated Healthy Subjects to Establish a Punch Biopsy Bleeding Model and to Evaluate the Effect of a 4-factor Prothrombin Complex Concentrate on Anticoagulation

NCT02047565

Bleeding

COMPLETED PHASE1

Relative Bioavailability and Pharmacodynamics of Dabigatran With Enoxaparin in Healthy Male and Female Volunteers

NCT02171559

Healthy

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Normal subjects will be dosed with PER977 or placebo alone and 1 week later, they will be given a single dose of edoxaban followed in 3 hours by a single IV dose of PER977. The purpose is to show safety and tolerability of PER977 alone and when combined with a NOAC (edoxaban). The study will also provide some insight into the doses that may be required to reverse a steady state edoxaban.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Anticoagulant Reversal Reversal of Edoxaban Induced Anticoagulation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

PER977-Dose 1

Dose titration

Group Type PLACEBO_COMPARATOR

PER977, Placebo

Intervention Type DRUG

PER977-Dose 2

Dose Titration

Group Type PLACEBO_COMPARATOR

PER977, Placebo

Intervention Type DRUG

PER977-Dose 3

Dose Titration

Group Type PLACEBO_COMPARATOR

PER977, Placebo

Intervention Type DRUG

PER977-Dose 4

Dose Titration

Group Type PLACEBO_COMPARATOR

PER977, Placebo

Intervention Type DRUG

PER977-Dose 5

Dose Titration

Group Type PLACEBO_COMPARATOR

PER977, Placebo

Intervention Type DRUG

PER977-Dose 6

Dose Titration

Group Type PLACEBO_COMPARATOR

PER977, Placebo

Intervention Type DRUG

PER977-Dose 7

Dose Titration

Group Type PLACEBO_COMPARATOR

PER977, Placebo

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PER977, Placebo

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

ciraparantag

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Adults age 18 to 45 years, inclusive
2. Laboratory values (chemistry, complete blood count coagulation assessments) and urinalysis performed during screening up to 21 days prior to administration of study treatment are within normal limits.
3. No clinically significant findings on 12-lead electrocardiogram (ECG) performed during screening.
4. Body mass index (BMI) 18 to ≤32 kg/m2, inclusive
5. Male subjects agree to use appropriate contraception (i.e., double barrier contraception such as a latex condom with spermicide with a female partner of child-bearing potential (a non-menopausal female who has not had one of the following: a) a hysterectomy (with or without oophorectomy), b) a bilateral oophorectomy without hysterectomy, or c) a medically documented ovarian failure) using a diaphragm or cervical cap or single barrier contraception if the female partner is using an intrauterine device or hormonal contraceptives or is sterilized; no barrier is required if the female partner has had a hysterectomy) when engaging in sexual activity during the course of the study. Moreover, male subjects should not donate sperm or attempt to impregnate a partner during the course of the study and for a period of 12 weeks following discharge from the study.
6. Female subjects of non-childbearing potential (a menopausal female with the above 3 definitions for menopause) agree to use two forms of non-hormonal contraceptive (e.g. barrier methods \[condom or diaphragm\]) or intrauterine device for the duration of the study and for 30 days following the completion of the study. Women are considered post-menopausal and not of child bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least six weeks ago. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of child bearing potential.
7. Nonsmokers or nonusers of nicotine containing products within 3 months of dosing (occasional use of tobacco products within 30 days of dosing will be considered on a case-by-case basis)
8. Subjects must understand and agree to comply with the requirements of the study and they must be willing to sign the informed consent form indicating voluntary consent to participate in the study prior to initiation of screening or study related activities.

Exclusion Criteria

1. History or current evidence of clinically significant cardiac, hepatic, renal, pulmonary, endocrine, neurologic, infectious, gastrointestinal, hematologic, or oncologic disease as determined by screening history, physical examination, laboratory test results or 12-lead ECG. History or current evidence of liver function tests greater than the upper limit of normal. History or current evidence of QTc Fridericia (QTcF) greater than normal (430±10 msec for males or 450±10 msec for females; average of three measurements).
2. History of unexplained syncope
3. Use of any drugs or substances known to be strong inhibitors or strong inducers of CYP3A4/5 transporters of p-glycoprotein within 28 days prior to the first dosing
4. History of major bleeding, trauma, surgical procedure of any type, or vaginal delivery within six months prior to screening
5. History of peptic ulcer, gastrointestinal bleeding (including hematemesis, melena, rectal bleeding) or bleeding from hemorrhoids within six months prior to screening
6. History of minor bleeding episodes such as epistaxis, rectal or hemorrhoidal bleeding (spots of blood on toilet paper) or gingival bleeding within 3 months prior to screening
7. Personal or family history of clotting disorder or abnormality, excessive bleeding, thrombovascular disease or any hematologic disorder involving platelets or clotting abnormalities or any condition requiring treatment with transfusions, anticoagulants or platelet inhibitors
8. Females with a history of dysfunctional uterine bleeding, including history of menorrhagia (heavy menstrual bleeding), metrorrhagia or polymenorrhea or current use of hormonal contraceptives.
9. Pregnant or breast-feeding
10. Male subjects with a history of hormone therapy within the 3 months prior to screening
11. Administration of any blood product or anticoagulant within 3 months prior to study entry or any non-steroidal anti-inflammatory drug or cyclooxygenase inhibitor within 2 weeks prior to screening
12. Taking any type of chronic medication within the 4 weeks prior to study entry
13. Positive serologic test for human immunodeficiency virus (HIV), Hepatitis C virus (HCV), or Hepatitis B surface antigen (HBsa)
14. Use of any of the following medications in the 4 weeks prior to study entry: rifampin, dronedarone, ketoconazole, verapamil, amiodarone, quinidine, clopidogrel, oral anticoagulants, or other agent known to interact with edoxaban
15. Donation of blood or blood products within 56 days prior to enrollment
16. Participation in any study with an investigational compound or device within 30 days prior to signing informed consent
17. Active drug, alcohol or nicotine use or dependence or any condition that, in the opinion of the Investigator, would interfere with adherence to study protocol

Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes